首页 > 最新文献

Haematologica最新文献

英文 中文
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-27 DOI: 10.3324/haematol.2024.286311
Rafael Colmenares, Noemi Alvarez, Eva Barragan, Blanca Boluda, Maria J Larrayoz, Maria Carmen Chillon, Elena Soria-Saldise, Cristina Bilbao, Joaquin Sanchez-Garcia, Teresa Bernal, David Martinez-Cuadron, Cristina Gil, Josefina Serrano, Carlos Rodriguez-Medina, Juan Bergua, Jose A Perez-Simon, Maria Calbacho, Juan M Alonso-Dominguez, Jorge Labrador, Mar Tormo, Pilar Herrera-Puente, Cristina Martin-Arriscado, Andres Arroyo-Barea, Inmaculada Rapado, Claudia Sargas, Iria Vazquez, Maria J Calasanz, Teresa Gomez-Casares, Ramon Garcia-Sanz, Rebeca Rodriguez-Veiga, Joaquin Martinez-Lopez, Rosa Ayala, Pau Montesinos, Pethema Group

Not available.

{"title":"Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry.","authors":"Rafael Colmenares, Noemi Alvarez, Eva Barragan, Blanca Boluda, Maria J Larrayoz, Maria Carmen Chillon, Elena Soria-Saldise, Cristina Bilbao, Joaquin Sanchez-Garcia, Teresa Bernal, David Martinez-Cuadron, Cristina Gil, Josefina Serrano, Carlos Rodriguez-Medina, Juan Bergua, Jose A Perez-Simon, Maria Calbacho, Juan M Alonso-Dominguez, Jorge Labrador, Mar Tormo, Pilar Herrera-Puente, Cristina Martin-Arriscado, Andres Arroyo-Barea, Inmaculada Rapado, Claudia Sargas, Iria Vazquez, Maria J Calasanz, Teresa Gomez-Casares, Ramon Garcia-Sanz, Rebeca Rodriguez-Veiga, Joaquin Martinez-Lopez, Rosa Ayala, Pau Montesinos, Pethema Group","doi":"10.3324/haematol.2024.286311","DOIUrl":"https://doi.org/10.3324/haematol.2024.286311","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ex vivo drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with PICALM::MLLT10.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-27 DOI: 10.3324/haematol.2024.286815
Elena Mastrodicasa, Luca Pagliaro, Valentina Pierini, Valentina Bardelli, Mariateresa Giaimo, Raffaella Zamponi, Anna Montanaro, Katia Tragni, Roberta Arcaleni, Maria Speranza Massei, Ilaria Capolsini, Katia Perruccio, Elena Varotto, Barbara Buldini, Andrea Gherli, Silvia Romoli, Caterina Matteucci, Maria Crocioni, Francesco Arcioni, Grazia Gurdo, Carla Cerri, Maurizio Caniglia, Giovanni Roti, Roberta La Starza

Not available.

{"title":"<i>Ex vivo</i> drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with <i>PICALM::MLLT10</i>.","authors":"Elena Mastrodicasa, Luca Pagliaro, Valentina Pierini, Valentina Bardelli, Mariateresa Giaimo, Raffaella Zamponi, Anna Montanaro, Katia Tragni, Roberta Arcaleni, Maria Speranza Massei, Ilaria Capolsini, Katia Perruccio, Elena Varotto, Barbara Buldini, Andrea Gherli, Silvia Romoli, Caterina Matteucci, Maria Crocioni, Francesco Arcioni, Grazia Gurdo, Carla Cerri, Maurizio Caniglia, Giovanni Roti, Roberta La Starza","doi":"10.3324/haematol.2024.286815","DOIUrl":"https://doi.org/10.3324/haematol.2024.286815","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in mortality rate after cancer-related thrombosis give hope for the future.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-27 DOI: 10.3324/haematol.2025.287430
Bengt Zöller

Not available.

不详。
{"title":"Trends in mortality rate after cancer-related thrombosis give hope for the future.","authors":"Bengt Zöller","doi":"10.3324/haematol.2025.287430","DOIUrl":"https://doi.org/10.3324/haematol.2025.287430","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Running chromosome analysis in leukemia or not, upfront or later?
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-27 DOI: 10.3324/haematol.2025.287346
Yanming Zhang

Not available.

{"title":"Running chromosome analysis in leukemia or not, upfront or later?","authors":"Yanming Zhang","doi":"10.3324/haematol.2025.287346","DOIUrl":"https://doi.org/10.3324/haematol.2025.287346","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia following Venetoclax plus Hypomethylating Agent Therapy.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-27 DOI: 10.3324/haematol.2024.286991
Isla M Johnson, Rimal Ilyas, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek Mangaonkar, Antoine Saliba, Mark R Litzow, William Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Not available.

{"title":"Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia following Venetoclax plus Hypomethylating Agent Therapy.","authors":"Isla M Johnson, Rimal Ilyas, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek Mangaonkar, Antoine Saliba, Mark R Litzow, William Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat","doi":"10.3324/haematol.2024.286991","DOIUrl":"https://doi.org/10.3324/haematol.2024.286991","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B-cell lymphoblastic leukemia/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-27 DOI: 10.3324/haematol.2024.286626
Emily N Alvey, Kai Lee Yap, Pamela Rathbun, Carrie Fitzpatrick, Shunyou Gong, Aida I Richardson

Not available.

{"title":"B-cell lymphoblastic leukemia/lymphoma with mutated <i>IKZF1</i> N159Y: clinical and genetic features of an emerging entity.","authors":"Emily N Alvey, Kai Lee Yap, Pamela Rathbun, Carrie Fitzpatrick, Shunyou Gong, Aida I Richardson","doi":"10.3324/haematol.2024.286626","DOIUrl":"https://doi.org/10.3324/haematol.2024.286626","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-20 DOI: 10.3324/haematol.2024.286043
Tuomas Lahteenmaki Taalas, Trausti Oskarsson, Mats Heyman, Bendik Lund, Kristi Lepik, Goda Vaitkevičiene, Olafur Gisli Jonsson, Julia Eriksson, Nina Toft, Laimonas Griškevičius, Helene Hallbook, Katrin Palk, Ulla Wartiovaara-Kautto, Petter Quist-Paulsen, Ulrika Noren-Nystrom, Kim Vettenranta, Jonas Abrahamsson, Kjeld Schmiegelow, Paivi M Lahteenmaki

Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol-appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at three-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS), hazard ratio 1.57 (95%CI 1.15-2.14) for patients 10-17.9 years, and 2.70 (2.03-3.58) for patients 18-45 years, compared to patients.

{"title":"Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial.","authors":"Tuomas Lahteenmaki Taalas, Trausti Oskarsson, Mats Heyman, Bendik Lund, Kristi Lepik, Goda Vaitkevičiene, Olafur Gisli Jonsson, Julia Eriksson, Nina Toft, Laimonas Griškevičius, Helene Hallbook, Katrin Palk, Ulla Wartiovaara-Kautto, Petter Quist-Paulsen, Ulrika Noren-Nystrom, Kim Vettenranta, Jonas Abrahamsson, Kjeld Schmiegelow, Paivi M Lahteenmaki","doi":"10.3324/haematol.2024.286043","DOIUrl":"https://doi.org/10.3324/haematol.2024.286043","url":null,"abstract":"<p><p>Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol-appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at three-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS), hazard ratio 1.57 (95%CI 1.15-2.14) for patients 10-17.9 years, and 2.70 (2.03-3.58) for patients 18-45 years, compared to patients.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic lymphocytic leukemia often arises by a multiclonal selection process.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-20 DOI: 10.3324/haematol.2024.286380
Davide Bagnara, Andrea N Mazzarello, Niccolò Cardente, Stefano Vergani, Siddha Kasar, Stacey Fernandes, Gerardo Ferrer, Fabio Ghiotto, Jacqueline C Barrientos, Jonathan E Kolitz, Kanti R Rai, Steven L Alen, Monica Colombo, Franco Fais, Jennifer R Brown, Manlio Ferrarini, Nicholas Chiorazzi

Although chronic lymphocytic leukemia (CLL) is diagnosed by identifying a circulating B-cell clone that exceeds 5x106/μL, additional distinct clones (ADC) have been identified in various studies. Notably, the numbers of ADC documented in these studies has increased as the various technologies evolved. To better define the frequency and the characteristics of ADCs in CLL, we used a Next Generation Sequencing (NGS) platform that affords high sequencing depth along with steps that limit overcounting to analyze IGHV-IGHD-IGHJ gene rearrangements in circulating CD5+ B cells from 57 patients. Notably, all patients had at least one ADC, in addition to the clinically relevant clone (CRC)., in 46 patients for whom lymphocyte count data were available, 44 had at least one ADC above the threshold of 1 B cell/μL, and remarkably, the average number of ADCs was 12 per patient. Notably, in two patients, the predominant ADC (pADC) qualified clinically as a separate CLL clone and in the in the remaining cases as low/high-count monoclonal B-cell lymphocytosis (MBL) clones. Moreover, in 11 patients studied longitudinally, pADCs were persistent and often increased in number. ADCs in patients with CLL exhibited fourfold more stereotyped IGHV-IGHD-IGH rearrangements than found in CD5+ B cells from healthy individuals, and IGHV use, somatic mutations, and Ig isotype distribution was similar between pADCs and CRCs. Thus, finding multiple expanded clones within the CD5+ B cells is the rule in patients with CLL, indicating that leukemogenesis is a multiclonal process that likely involves competition among B cells with special BCR features.

{"title":"Chronic lymphocytic leukemia often arises by a multiclonal selection process.","authors":"Davide Bagnara, Andrea N Mazzarello, Niccolò Cardente, Stefano Vergani, Siddha Kasar, Stacey Fernandes, Gerardo Ferrer, Fabio Ghiotto, Jacqueline C Barrientos, Jonathan E Kolitz, Kanti R Rai, Steven L Alen, Monica Colombo, Franco Fais, Jennifer R Brown, Manlio Ferrarini, Nicholas Chiorazzi","doi":"10.3324/haematol.2024.286380","DOIUrl":"https://doi.org/10.3324/haematol.2024.286380","url":null,"abstract":"<p><p>Although chronic lymphocytic leukemia (CLL) is diagnosed by identifying a circulating B-cell clone that exceeds 5x106/μL, additional distinct clones (ADC) have been identified in various studies. Notably, the numbers of ADC documented in these studies has increased as the various technologies evolved. To better define the frequency and the characteristics of ADCs in CLL, we used a Next Generation Sequencing (NGS) platform that affords high sequencing depth along with steps that limit overcounting to analyze IGHV-IGHD-IGHJ gene rearrangements in circulating CD5+ B cells from 57 patients. Notably, all patients had at least one ADC, in addition to the clinically relevant clone (CRC)., in 46 patients for whom lymphocyte count data were available, 44 had at least one ADC above the threshold of 1 B cell/μL, and remarkably, the average number of ADCs was 12 per patient. Notably, in two patients, the predominant ADC (pADC) qualified clinically as a separate CLL clone and in the in the remaining cases as low/high-count monoclonal B-cell lymphocytosis (MBL) clones. Moreover, in 11 patients studied longitudinally, pADCs were persistent and often increased in number. ADCs in patients with CLL exhibited fourfold more stereotyped IGHV-IGHD-IGH rearrangements than found in CD5+ B cells from healthy individuals, and IGHV use, somatic mutations, and Ig isotype distribution was similar between pADCs and CRCs. Thus, finding multiple expanded clones within the CD5+ B cells is the rule in patients with CLL, indicating that leukemogenesis is a multiclonal process that likely involves competition among B cells with special BCR features.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-20 DOI: 10.3324/haematol.2024.286027
Ofrat Beyar-Katz, Kai Rejeski, Roni Shouval

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematologic malignancies. However, it is frequently complicated by immune effector cell-associated hematotoxicity (ICAHT), a potentially life-threatening adverse event encompassing neutropenia, anemia, and thrombocytopenia. These cytopenias elevate the risk of severe infections, transfusion dependence, and prolonged hospital stays, contributing substantially to morbidity and non-relapse mortality. This review delineates the incidence, mechanisms, and risk factors for ICAHT, highlighting the complex interplay between disease burden, patient immune status, and CAR-T product features. Standardized grading systems, based on the depth and duration of neutropenia, have improved ICAHT classification and enabled more consistent risk stratification. Current prophylactic and therapeutic strategies ranging from growth factor administration to hematopoietic stem cell boosts for refractory cases are discussed, emphasizing tailored approaches to mitigate severe and prolonged hematotoxicity. These management strategies highlight the need for targeted interventions to prevent ICAHT without compromising CAR-T efficacy. As CAR-T therapy broadens to new indications, optimized ICAHT management could enhance patient outcomes, reduce healthcare utilization, and increase therapy accessibility.

{"title":"Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.","authors":"Ofrat Beyar-Katz, Kai Rejeski, Roni Shouval","doi":"10.3324/haematol.2024.286027","DOIUrl":"https://doi.org/10.3324/haematol.2024.286027","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematologic malignancies. However, it is frequently complicated by immune effector cell-associated hematotoxicity (ICAHT), a potentially life-threatening adverse event encompassing neutropenia, anemia, and thrombocytopenia. These cytopenias elevate the risk of severe infections, transfusion dependence, and prolonged hospital stays, contributing substantially to morbidity and non-relapse mortality. This review delineates the incidence, mechanisms, and risk factors for ICAHT, highlighting the complex interplay between disease burden, patient immune status, and CAR-T product features. Standardized grading systems, based on the depth and duration of neutropenia, have improved ICAHT classification and enabled more consistent risk stratification. Current prophylactic and therapeutic strategies ranging from growth factor administration to hematopoietic stem cell boosts for refractory cases are discussed, emphasizing tailored approaches to mitigate severe and prolonged hematotoxicity. These management strategies highlight the need for targeted interventions to prevent ICAHT without compromising CAR-T efficacy. As CAR-T therapy broadens to new indications, optimized ICAHT management could enhance patient outcomes, reduce healthcare utilization, and increase therapy accessibility.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-20 DOI: 10.3324/haematol.2024.286559
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven Kornblau, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero

Not available.

{"title":"A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.","authors":"Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven Kornblau, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero","doi":"10.3324/haematol.2024.286559","DOIUrl":"https://doi.org/10.3324/haematol.2024.286559","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Haematologica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1